CHAD Therapeutics Launches Advanced New Oxygen Conserver and Next-Generation Oxygen Transfilling System at Medtrade Show in Las

  
    
  
  
    
      CHAD Therapeutics, Inc. (AMEX:CTU) today announced the launch of 
      an advanced pneumatic oxygen conserver and its next-generation oxygen 
      transfilling system at the Medtrade show in Las Vegas.
    
    
      CHAD's advanced BONSAITM pneumatic conserver is 
      an important addition to the Company's extensive line of oxygen 
      conserving devices. "With its sleek, lightweight design (less than 10 
      ounces), conserving ratio of up to 6:1, eight settings, and an 
      adjustable continuous flow feature, BONSAI reinforces CHAD's 
      longstanding leadership in the oxygen conserver market. A pneumatic 
      conserving device that offers a 6:1 savings ratio while ensuring 
      adequate oxygen saturation for patients is a groundbreaking 
      achievement," said President and CEO Earl Yager. CHAD currently expects 
      to receive FDA clearance to market and be able to begin shipping this 
      new device in May.
    
    
      Yager continued, "CHAD's next-generation oxygen transfilling system, the 
      OMNI line, is a significant upgrade to CHAD's pioneering TOTAL O2® 
      Home Oxygen Delivery System that meets the needs of a broader range of 
      oxygen patients than ever before and gives homecare providers a powerful 
      tool to reduce operating costs and take advantage of the new Medicare 
      transfilling reimbursement category that took effect on January 1, 2007."
    
    
      The OMNI 2 is designed for the specific requirements of pediatric 
      patients. The OMNI 5 offers increased oxygen delivery of up to 5 liters 
      per minute. In addition to providing stationary oxygen, both devices can 
      also refill a wide variety of portable oxygen cylinders in the patient's 
      home, thus eliminating the cost for the homecare provider and 
      inconvenience for the patient of having to periodically collect and 
      refill oxygen cylinders at a remote depot.
    
    
      "Our new BONSAI and OMNI devices demonstrate CHAD's commitment to 
      technology that improves patient care while lowering operating costs for 
      homecare providers," the CEO added.
    
    
      About CHAD Therapeutics
    
    
      CHAD Therapeutics, Inc. develops, manufactures and markets respiratory 
      care devices designed to improve the efficiency of oxygen delivery 
      systems for home health care and hospital treatment of patients 
      suffering from pulmonary diseases. For more information, visit www.CHADtherapeutics.com.
    
    
      Safe Harbor Statements under the Private Securities Litigation 
      Reform Act of 1995.
    
    
      The foregoing statements regarding prospects for future earnings and 
      revenues, future sales trends and the introduction of products under 
      development are forward-looking statements that involve certain risks 
      and uncertainties. A number of important factors could cause 
      actual results to differ materially from those contemplated by such 
      forward-looking statements. These include the loss of one or more 
      major customers, increased competition, the introduction of new products 
      with perceived competitive advantages over the Company's products, 
      changes or proposed changes in health care reimbursement which affect 
      home care providers and CHAD's ability to anticipate and respond to 
      technological and economic changes in the home oxygen market. Moreover, 
      the success of the Company's products and products under development 
      will depend on their efficacy, reliability and the health care 
      community's perception of the products' capabilities and benefits, the 
      degree of acceptance the products achieve among homecare providers and, 
      with respect to products under development, obtaining timely regulatory 
      approval. Additional factors that could cause actual results to 
      differ materially from those contemplated in this press release can be 
      found in the Company's annual and quarterly reports filed with the 
      Securities and Exchange Commission under the caption "Outlook: Issues 
      and Risks."